Pharmaceutisch Weekblad

, Volume 14, Issue 5, pp 297–304 | Cite as

Didanosine, a new antiretroviral drug

A review
  • R. M. E. Franssen
  • P. L. Meenhorst
  • C. H. W. Koks
  • J. H. Beijnen


In this article the literature about didanosine, an antiretroviral drug, is reviewed. The mechanism of action, biochemical pharmacology, pharmacokinetics, and clinical results of phase-I trials are discussed. Serious adverse effects such as pancreatitis and peripheral neuropathy have occurred in these trials. An antiretroviral effect was observed in terms of an increase in CD4+ lymphocytes and a decrease in p24 antigen levels in HIV-infected individuals. Didanosine seems to be a promising drug against HIV infection, but knowledge about its clinical efficacy is scanty.


Biochemistry Didanosine Drug evaluation Pharmacokinetics Pharmacology Side effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′,3′-deoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321:726–38.PubMedGoogle Scholar
  2. 2.
    Groopman JE. Zidovudine intolerance. Rev Infect Dis 1990;12(suppl 5):S500–6.PubMedGoogle Scholar
  3. 3.
    Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, et al. The AZT Collaborative Working Group. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989;262:2405–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff Lehrman S, Gallo RC, et al. 3′-Azido-3′deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virusin vitro. Proc Natl Acad Sci USA 1985;82:7096–100.PubMedGoogle Scholar
  5. 5.
    Johnson M, Caiazzo T, Molina J-M, Donahue R, Groopman J. Inhibition of bone marrow myelopoiesis and erythropoiesisin vitro by anti-retroviral nucleoside derivatives. Br J Haematol 1988;70:137–41.PubMedGoogle Scholar
  6. 6.
    Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematological disorders. Blood 1989;74:1455–63.PubMedGoogle Scholar
  7. 7.
    Groopman JE. Current advances in the diagnosis and treatment of AIDS: an introduction. Rev Infect Dis 1990;12:908–11.PubMedGoogle Scholar
  8. 8.
    Gertner E, Thurn JR, Williams DN, Simpson M, Balfour HH Jr, Rhame F, et al. Zidovudine-associated myopathy. Am J Med 1898;87:814–8.Google Scholar
  9. 9.
    Helbert M, Fletcher T, Peddle B, Harris JRW, Pinching AJ. Zidovudine-associated myopathy. Lancet 1988;2:689–90.CrossRefGoogle Scholar
  10. 10.
    Bessen LJ, Greene JB, Louie E, Seitzman P, Weinberg H. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N Engl J Med 1988;318:708.Google Scholar
  11. 11.
    Gorard DA, Henry K, Guiloff RJ. Necrotising myopathy and zidovudine. Lancet 1988;1:1050.CrossRefPubMedGoogle Scholar
  12. 12.
    Richman DD, Fischl MA, Grieco MH, Gottlieb MH, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS or AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7.PubMedGoogle Scholar
  13. 13.
    Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, et al. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1333–40PubMedGoogle Scholar
  14. 14.
    Cooley PC, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, et al. Treatment of AIDS and AIDS-related complex with 2′,3′-dideoxyinosine. Rev Infect Dis 1990;12(suppl 5):S552–60.PubMedGoogle Scholar
  15. 15.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4.PubMedGoogle Scholar
  16. 16.
    Richman DD. Zidovudine resistance of human immunodeficiency virus. Rev Infect Dis 1990;12(suppl 5):S507–12.PubMedGoogle Scholar
  17. 17.
    Mitsuya H, Broder S. Inhibition of thein vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911–5.PubMedGoogle Scholar
  18. 18.
    Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 1987;315:773–8.CrossRefGoogle Scholar
  19. 19.
    Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, et al. Inhibition of human immunodeficiency virus (HIV-I/HTLV-III/Ba-c) replication in fresh and cultural human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111–25.CrossRefPubMedGoogle Scholar
  20. 20.
    Molina JM, Groopman JE. Bone marrow toxicity of dideoxyinosine. N Engl J Med 1989;321:1478.Google Scholar
  21. 21.
    Du DL, Volpe DA, Grieshaber CK, Murphy MJ.In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 1990;18:823–36.Google Scholar
  22. 22.
    McGowan JJ, Tomaszewski JE, Cradock J, Hoth D, Grieshaber CK, Broder S, et al. Overview of the preclinical development of an antiretoviral drug 2′,3′-dideoxyinosine. Rev Infect Dis 1990;12(suppl 5):S513–21.PubMedGoogle Scholar
  23. 23.
    Ahluwalia G, Cooney DA, Mitsuya H, Fridland A, Flora KP, Hao Z, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987;36:3797–800.PubMedGoogle Scholar
  24. 24.
    Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Marczyk KS, Broder S, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990;47:647–54.PubMedGoogle Scholar
  25. 25.
    Johnson MA, Ahluwalia G, Connelley MC, Cooney DA, Broder S, Johns DG, et al. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxysadenosine in human lymphoid cells. J Biol Chem 1988;263:15354–7.PubMedGoogle Scholar
  26. 26.
    Stryer L. Biochemistry. 2nd ed. San Fransisco: W.H. Freeman and Company, 1975.Google Scholar
  27. 27.
    Myers MW. New antiretroviral agants in the clinic. Rev Infect Dis 1990;12:944–50.PubMedGoogle Scholar
  28. 28.
    Hirsch MS. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis 1990;161:845–57.PubMedGoogle Scholar
  29. 29.
    Mitsuya H, Jarret RF, Matsukura M, Di Marzo Veronese F, DeVico AL, Sarngadharan MG, et al. Long-term inhibition of human lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T-cells protected by 2′,3′-dideoxynucleosidesin vitro. Proc Natl Acad Sci USA 1987;84:2033–7.PubMedGoogle Scholar
  30. 30.
    Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333–7.PubMedGoogle Scholar
  31. 31.
    Starnes MC, Cheng YC. Cellular metabolism of 2′,3′dideoxycytidine, a compound active against human immunodeficiency virusin vitro. J Biol Chem 1987;262:988–91.PubMedGoogle Scholar
  32. 32.
    Waqar MA, Evans MJ, Manley KF, Hughes RG, Huberman JA. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984;121:402–8.PubMedGoogle Scholar
  33. 33.
    Mitsuya H, Dahlberg JE, Spigelman Z, et al. 2′,3′Dideoxynucleosides: broad spectrum antiretroviral activity and mechanism of action. In: Bolognesi D, ed. Human retroviruses, cancer, and AIDS: approaches to prevention and therapy. New York: Alan R. Liss, 1988:407–21.Google Scholar
  34. 34.
    Blau PA, Hines JW, Voyksner RD. Application of high-performance liquid chromatography and thermospray high-performance liquid chromatography-mass spectrometry to the analysis and identification of 2′,3′-dideoxyadenosine and its metabolite in biological media. J Chromatogr 1987;420:1–12.PubMedGoogle Scholar
  35. 35.
    Carpen ME, Poplack DG, Pizzo PA, Balis FM. Highperformance liquid chromatographic method for analysis of 2′,3′-dideoxyinosine in human body fluids. J Chromatogr 1990;526:69–75.PubMedGoogle Scholar
  36. 36.
    Kalin JR, Hill DL. Determination of 2′,3′-dideoxyadenosine, 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine in biological samples. J Chromatogr 1988;431:184–91.PubMedGoogle Scholar
  37. 37.
    Ray G, Murril E. Determination of 2′,3′-dideoxyinosine in plasma by high performance liquid chromatography. Anal Lett 1987;20:1815–38.Google Scholar
  38. 38.
    Beijnen JH, Meenhorst PL, Rosing H, Van Gijn R, Los G, Underberg WJM. Analysis of 2′,3′-dideoxyinosine (ddI) in plasma by isocratic high performance liquid chromatography with ultraviolet detection. J Drug Dev 1990;3:127–33.Google Scholar
  39. 39.
    Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1987;36:1765–8.PubMedGoogle Scholar
  40. 40.
    Russel JW, Klunk LJ. Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem Pharmacol 1990;38:1385–8.CrossRefGoogle Scholar
  41. 41.
    Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, et al. The National Cancer Institute Phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990;12(suppl 5):S522–33.PubMedGoogle Scholar
  42. 42.
    Valentine FT, Seidlin M, Hochster H, Laverty M. Phase I study of 2′,3′-dideoxyinosine: experience with 19 patients at the New York University Medical Center. Rev Infect Dis 1990;12(suppl 5):S534–9.PubMedGoogle Scholar
  43. 43.
    Dolin RD, Lambert JS, Morse GD, Reichman RC, Plank CS, Reid J, et al. 2′,3′-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis 1990;12(suppl 5):S540–51.PubMedGoogle Scholar
  44. 44.
    Yarchoan R, Mitsuya H, Thomas RV, Pluda JM, Hartman NR, Perno CF, et al.In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989;245:412–5.PubMedGoogle Scholar
  45. 45.
    Qian M, Finco TS, Swagler AR, Gallo JM. Pharmacokinetics of 2′,3′-dideoxyinosine in monkeys. Antimicrob Agents Chemother 1991;35:1247–9.PubMedGoogle Scholar
  46. 46.
    Ho DD. The acquired immunodeficiency syndrome (AIDS) dementia complex. Ann Int Med 1989;111:400–10.PubMedGoogle Scholar
  47. 47.
    Teresaki T, Pardridge WM. Restricted transport of 3′azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis 1988;158:630–2.PubMedGoogle Scholar
  48. 48.
    Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, El-Amin D, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137–44.PubMedGoogle Scholar
  50. 50.
    Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Kim Lyerly H, Durack DT, et al. Administration of 3′-azido-3′-dideoxythymidine, an inhibitor of HTLV-III/LAV replication to patients with AIDS or AIDS-related complex. Lancet 1986;1:575–80.CrossRefPubMedGoogle Scholar
  51. 51.
    Yarchoan R, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, et al. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987;1:132–5.PubMedGoogle Scholar
  52. 52.
    Anderson BA, Hoesterey BL, Baker DC, Galinsky RE. Uptake kinetics of 2′,3′-dideoxyinosine into the brain and cerebrospinal fluid of rats: intravenous infusion studies. J Pharm Exp Ther 1990;253:113–8.Google Scholar
  53. 53.
    Cooley TP, Kunchers LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, et al. Once daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1340–5.PubMedGoogle Scholar
  54. 54.
    Bouvet E, Casalino E, Prevost MH, Vachon F. Fatal case of 2′,3′-dideoxymosine-associated pancreatitis. Lancet 1990;336:1515.CrossRefGoogle Scholar
  55. 55.
    Goldspiel BR. Status of dideoxyinosine in clinical trials. Am J Hosp Pharm 1991;48:1298–9.PubMedGoogle Scholar
  56. 56.
    Bach MC. Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine. N Engl J Med 1990;3223:275.Google Scholar
  57. 57.
    Kew Hai K, Gaup JL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 1991;115:283–4.PubMedGoogle Scholar
  58. 58.
    Lafeuillade A, Aubert L, Chaffanjon P, Quilichini R. Optic neuritis associated with dideoxyinosine. Lancet 1991;337:615–6.CrossRefGoogle Scholar
  59. 59.
    Mills J, Masur H. AIDS-related infections. Sci Am 1990;8:32–9.Google Scholar
  60. 60.
    Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, et al. The reservoir for HIV in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:305–8.PubMedGoogle Scholar
  61. 61.
    Lane HC. Virologic and immunologic aspects of acquired immunodeficiency syndrome. Surg Gyn Obst 1990;171:11–8.PubMedGoogle Scholar
  62. 62.
    Herer B, Chinet T, Labrune S, Collignon MA, Chretien J, Huchon G. Pancreatitis associated with pentamidine by aerosol. BMJ 1990;298:605.Google Scholar
  63. 63.
    Grunfeld C, Kotter DP, Hamadeh R, Tierney A, Wang J, Pierson RN Jr. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27–31.CrossRefGoogle Scholar
  64. 64.
    Goldspiel BR. Availability of dideoxyinosine. Am J Hosp Pharm 1991;48:1299–300.PubMedGoogle Scholar
  65. 65.
    Williams P. Panel cautiously recommends dideoxyinosine approval. ASM News 1991;57:500–1.Google Scholar
  66. 66.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557–9.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • R. M. E. Franssen
    • 1
  • P. L. Meenhorst
    • 2
  • C. H. W. Koks
    • 1
  • J. H. Beijnen
    • 1
  1. 1.Department of PharmacySlotervaart HospitalEC AmsterdamThe Netherlands
  2. 2.Department of Internal MedicineSlotervaart HospitalThe Netherlands

Personalised recommendations